|
1
|
Doody KM, Bussières-Marmen S, Li A, et al:
T cell protein tyrosine phosphatase deficiency results in
spontaneous synovitis and subchondral bone resorption in mice.
Arthritis Rheum. 64:752–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klijn RJ, van den Beucken JJ, Bronkhorst
EM, et al: Predictive value of ridge dimensions on autologous bone
graft resorption in staged maxillary sinus augmentation surgery
using Cone-Beam CT. Clin Oral Implants Res. 23:409–415. 2012.
View Article : Google Scholar
|
|
3
|
Nonaka CF, Cavalcante RB, Nogueira RL, et
al: Immunohistochemical analysis of bone resorption regulators
(RANKL and OPG), angiogenic index, and myofibroblasts in syndrome
and non-syndrome odontogenic keratocysts. Arch Oral Biol.
57:230–237. 2012. View Article : Google Scholar
|
|
4
|
Hong ZQ, Tao LM and Li L: Effect of stress
on mRNA expression of H+-ATPase in osteoclasts. Mol Cell
Biochem. 343:183–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakayama T, Mizoguchi T, Uehara S, et al:
Polarized osteoclasts put marks of tartrate-resistant acid
phosphatase on dentin slices - a simple method for identifying
polarized osteoclasts. Bone. 49:1331–1339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fujisaki K, Tanabe N, Suzuki N, et al:
Receptor activator of NF-kappaB ligand induces the expression of
carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9
in osteoclast precursor RAW264.7 cells. Life Sci. 80:1311–1318.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Q, Liang X, Zhu B, et al: Effects of
fluid shear stress on mRNA expression of carbonic anhydrase II in
polarized rat osteoclasts. Cell Biol Int. 30:714–720. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goettsch C, Rauner M, Sinningen K, et al:
The osteoclast-associated receptor (OSCAR) is a novel receptor
regulated by oxidized low-density lipoprotein in human endothelial
cells. Endocrinology. 152:4915–4926. 2011. View Article : Google Scholar
|
|
9
|
Ishikawa S, Arase N, Suenaga T, et al:
Involvement of FcRgamma in signal transduction of
osteoclast-associated receptor (OSCAR). Int Immunol. 16:1019–1025.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH, Kim K, Jin HM, et al: Upstream
stimulatory factors regulate OSCAR gene expression in
RANKL-mediated osteoclast differentiation. J Mol Biol. 383:502–511.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JH, Kim K, Youn BU, et al: MHC class
II transactivator negatively regulates RANKL-mediated osteoclast
differentiation by downregulating NFATc1 and OSCAR. Cell Signal.
22:1341–1349. 2010. View Article : Google Scholar
|
|
12
|
Kovacić N, Lukić IK, Grcević D, et al: The
Fas/Fas ligand system inhibits differentiation of murine
osteoblasts but has a limited role in osteoblast and osteoclast
apoptosis. J Immunol. 178:3379–3389. 2007.PubMed/NCBI
|
|
13
|
Krum SA, Miranda-Carboni GA, Hauschka PV,
et al: Estrogen protects bone by inducing Fas ligand in osteoblasts
to regulate osteoclast survival. EMBO J. 27:535–545. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura T, Imai Y, Matsumoto T, et al:
Estrogen prevents bone loss via estrogen receptor alpha and
induction of Fas ligand in osteoclasts. Cell. 130:811–823. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boanini E, Torricelli P, Gazzano M, et al:
Alendronate-hydroxy- apatite nanocomposites and their interaction
with osteoclasts and osteoblast-like cells. Biomaterials.
29:790–796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawata T, Tenjou K, Tokimasa C, et al:
Effect of alendronate on osteoclast differentiation and bone volume
in transplanted bone. Exp Anim. 53:47–51. 2004.PubMed/NCBI
|
|
17
|
Moon HJ, Yun YP, Han CW, et al: Effect of
heparin and alendronate coating on titanium surfaces on inhibition
of osteoclast and enhancement of osteoblast function. Biochem
Biophys Res Commun. 413:194–200. 2011. View Article : Google Scholar
|
|
18
|
Panzavolta S, Torricelli P, Bracci B, et
al: Alendronate and Pamidronate calcium phosphate bone cements:
setting properties and in vitro response of osteoblast and
osteoclast cells. J Inorg Biochem. 103:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rogers MJ, Frith JC, Luckman SP, et al:
Molecular mechanisms of action of bisphosphonates. Bone.
24:73S–79S. 1999. View Article : Google Scholar
|
|
20
|
Sugata Y, Sotome S, Yuasa M, et al:
Effects of the systemic administration of alendronate on bone
formation in a porous hydroxyapatite/collagen composite and
resorption by osteoclasts in a bone defect model in rabbits. J Bone
Joint Surg Br. 93:510–516. 2011. View Article : Google Scholar
|
|
21
|
Sama AA, Khan SN, Myers ER, et al:
High-dose alendronate uncouples osteoclast and osteoblast function:
a study in a rat spine pseudarthrosis model. Clin Orthop Relat Res.
425:135–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koshihara Y, Kodama S, Ishibashi H, et al:
Reversibility of alendronate-induced contraction in human
osteoclast-like cells formed from bone marrow cells in culture. J
Bone Miner Metab. 17:98–107. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Breuil V, Cosman F, Stein L, et al: Human
osteoclast formation and activity in vitro: effects of alendronate.
J Bone Miner Res. 13:1721–1729. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong ZQ, Tao LM and Li L: mRNA expression
in osteoclasts: a chronobiological approach. Biological Rhythm
Research. 42:287–298. 2011. View Article : Google Scholar
|
|
25
|
D’Amelio P, Grimaldi A, Cristofaro MA, et
al: Alendronate reduces osteoclast precursors in osteoporosis.
Osteoporos Int. 21:1741–1750. 2010.PubMed/NCBI
|
|
26
|
Fisher JE, Rogers MJ, Halasy JM, et al:
Alendronate mechanism of action: geranylgeraniol, an intermediate
in the mevalonate pathway, prevents inhibition of osteoclast
formation, bone resorption, and kinase activation in vitro. Proc
Natl Acad Sci USA. 96:133–138. 1999. View Article : Google Scholar
|
|
27
|
Sato M, Grasser W, Endo N, et al:
Bisphosphonate action. Alendronate localization in rat bone and
effects on osteoclast ultrastructure. J Clin Invest. 88:2095–2105.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Owens JM, Fuller K and Chambers TJ:
Osteoclast activation: potent inhibition by the bisphosphonate
alendronate through a nonresorptive mechanism. J Cell Physiol.
172:79–86. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Q, Badell IR, Schwarz EM, et al:
Tumor necrosis factor prevents alendronate-induced osteoclast
apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Arthritis Rheum. 52:2708–2718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang XM, Yu SF and Yang ZP: Apoptosis of
osteoclast-like cells induced by alendronate is related to Fas gene
expression. Chin J Dent Res. 3:26–32. 2000.PubMed/NCBI
|
|
31
|
Halasy-Nagy JM, Rodan GA and Reszka AA:
Inhibition of bone resorption by alendronate and risedronate does
not require osteoclast apoptosis. Bone. 29:553–559. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alakangas A, Selander K, Mulari M, et al:
Alendronate disturbs vesicular trafficking in osteoclasts. Calcif
Tissue Int. 70:40–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kum KY, Park JH, Yoo YJ, et al: The
inhibitory effect of alendronate and taurine on osteoclast
differentiation mediated by Porphyromonas gingivalis sonicates in
vitro. J Endod. 29:28–30. 2003. View Article : Google Scholar
|
|
34
|
Colucci S, Minielli V, Zambonin G, et al:
Alendronate reduces adhesion of human osteoclast-like cells to bone
and bone protein-coated surfaces. Calcif Tissue Int. 63:230–235.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmidt A, Rutledge SJ, Endo N, et al:
Protein-tyrosine phosphatase activity regulates osteoclast
formation and function: inhibition by alendronate. Proc Natl Acad
Sci USA. 93:3068–3073. 1996. View Article : Google Scholar
|
